RT Journal Article
SR Electronic
T1 The National Registry of Rare Kidney Diseases (RaDaR): Description, recruitment, and cross-sectional analyses of 25,880 adults and children with rare kidney diseases in the UK
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.24.23296009
DO 10.1101/2023.09.24.23296009
A1 Wong, Katie
A1 Pitcher, David
A1 Braddon, Fiona
A1 Downward, Lewis
A1 Steenkamp, Retha
A1 Annear, Nicholas
A1 Barratt, Jonathan
A1 Bingham, Coralie
A1 Coward, Richard J.
A1 Chrysochou, Tina
A1 Game, David
A1 Griffin, Sian
A1 Hall, Matt
A1 Johnson, Sally
A1 Kanigicherla, Durga
A1 Frankl, Fiona Karet
A1 Kavanagh, David
A1 Kerecuk, Larissa
A1 Maher, Eamonn R.
A1 Moochhala, Shabbir
A1 Pinney, Jenny
A1 Sayer, John A.
A1 Simms, Roslyn
A1 Sinha, Smeeta
A1 Srivastava, Shalabh
A1 Tam, Frederick W. K.
A1 Thomas, Kay
A1 Neil Turner, A.
A1 Walsh, Stephen B.
A1 Waters, Aoife
A1 Wilson, Patricia
A1 Wong, Edwin
A1 RaDaR consortium
A1 Therese L. Sy, Karla
A1 Huang, Kui
A1 Ye, Jamie
A1 Nitsch, Dorothea
A1 Saleem, Moin
A1 Bockenhauer, Detlef
A1 Bramham, Kate
A1 Gale, Daniel P.
YR 2023
UL http://medrxiv.org/content/early/2023/11/25/2023.09.24.23296009.abstract
AB Rare kidney diseases are not well characterised, despite making a significant contribution to the burden of kidney disease globally. The National Registry of Rare Kidney Diseases (RaDaR) collects longitudinal disease and treatment-related data from people living with rare kidney diseases across the UK, and is the largest rare kidney disease registry in the world. We present the clinical demographics and renal function of 25,880 prevalent patients and evaluate for any potential recruitment bias to RaDaR.RaDaR has automatic linkage with the UK Renal Registry (UKRR, with which all UK patients receiving Kidney Replacement Therapy (KRT) are registered). To assess for recruitment bias to RaDaR, ethnicity and socioeconomic status of 1) prevalent RaDaR patients receiving KRT were compared with patients with eligible rare disease diagnoses receiving KRT in the UKRR 2) patients recruited to RaDaR and all eligible unrecruited patients at two renal centres were compared 3) the age-stratified ethnicity distribution of RaDaR patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) was compared to the English Census.We found evidence of some disparities in ethnicity and social deprivation in recruitment to RaDaR, however these were not consistent across all comparisons. Predominant rare kidney diseases in adults were ADPKD (29.2%), Vasculitis (15.8%) and IgA nephropathy (15.7%), compared to Idiopathic nephrotic syndrome (43.6%), Vasculitis (10.8%) and Alport Syndrome (5.9%) in children. Compared with either adults recruited to RaDaR or the English population, children recruited to RaDaR were more likely to be of Asian ethnicity and live in more socially deprived areas.Lay Summary Rare kidney diseases make a significant contribution to the number of people living with kidney disease globally: >25% of adults and >50% of children with kidney failure have a rare disease. However, there is a lack of high-quality published data on how these conditions present, and in which patient groups. Patients often face delays in diagnosis and lack of reliable information on their condition once diagnosed. The UK National Registry of Rare Kidney Diseases (RaDaR) was formed in 2010 to address this knowledge gap. It collects long-term data for UK patients with rare kidney conditions, and is the largest rare kidney disease registry in the world. Here, we present information about 25,880 adults and children recruited to RaDaR, including ethnicity, socioeconomic status, and kidney function, and investigate whether there is any bias in recruitment to RaDaR. To our knowledge, this is the largest epidemiological description of rare kidney diseases worldwide.Competing Interest StatementKatie Wong, David Pitcher, Fiona Braddon, Retha Steenkamp, Lewis Downward, Nicholas Annear, Jonathan Barratt, Coralie Bingham, Kate Bramham , Richard J. Coward, Tina Chrysochou, David Game, Sian Griffin, Matthew Hall, Sally Johnson, Durga Kanigicherla, Fiona Karet Frankl, David Kavanagh, Larissa Kerecuk, Shabbir Moochhala, Jennifer Pinney, John A. Sayer, Roslyn Simms, Smeeta Sinha, Shalabh Srivastava, Frederick W. K. Tam, Kay Thomas, A. Neil Turner, Stephen B. Walsh, Aoife Waters, Patricia Wilson, Edwin Wong, Dorothea Nitsch, Detlef Bockenhauer declare no competing interests as they relate to the current manuscript. Karla Therese L. Sy, Kui Huang and Jamie Ye declare employment with Pfizer Inc. Eamonn R. Maher declares support for the current manuscript from VHL UK/Ireland. Moin Saleem declares support for the current manuscript from a Medical Research Council UK Precision Medicine program grant - MR/R013942/1. Daniel P Gale declares support for the current manuscript from the Medical Research Council, Kidney Research UK, Kidney Care UK, and Polycystic Kidney Disease Charity (payments to institution).Funding StatementRaDaR has received support from The UK Medical Research Council, Kidney Research UK, Kidney Care UK and the Polycystic Kidney Disease Charity. This study was partly supported by Pfizer Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics committee of NHS South-West-Central Bristol gave ethical approval for this work (19/SW/0173)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe minimal underlying dataset cannot be included as it contains confidential, potentially identifying and sensitive patient information. The UK Kidney Association(UKKA) is the controller of the data and restricts sharing of individual level data if there is no direct relationship between the UKKA and the recipient. The data underlying these results are available for researchers who meet the criteria for access to confidential data.